Bielasz Jennifer Kathleen Form 3 March 17, 2011

### FORM 3

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

**SECURITIES** 

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person \* Statement ARENA PHARMACEUTICALS INC [ARNA] A Bielasz Jennifer Kathleen (Month/Day/Year) 03/15/2011 (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) C/O ARENA (Check all applicable) PHARMACEUTICALS, INC.. 6166 NANCY RIDGE 10% Owner Director **DRIVE** \_X\_\_ Officer Other (give title below) (specify below) (Street) 6. Individual or Joint/Group Sr. Dir. of Accounting & Cont. Filing(Check Applicable Line) \_X\_ Form filed by One Reporting Person SAN DIEGO, CAÂ 92121 Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned 4. Nature of Indirect Beneficial 1. Title of Security 2. Amount of Securities Beneficially Owned Ownership Ownership (Instr. 4) (Instr. 4) (Instr. 5) Form: Direct (D) or Indirect (Instr. 5) Â Common Stock 7,666 D Reminder: Report on a separate line for each class of securities beneficially SEC 1473 (7-02) owned directly or indirectly. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 4)

2. Date Exercisable and (Instr. 4)

Expiration Date (Month/Day/Year)

Output

A mount of 4.

Securities Underlying Derivative Security

Output

Conversion Ownership Ovnership or Exercise

Form of (Instr. 5)

#### Edgar Filing: Bielasz Jennifer Kathleen - Form 3

	Date Exercisable	Expiration Date	(Instr. 4) Title	Amount or Number of Shares	Price of Derivative Security	Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	
Employee Stock Option (right to buy)	(1)	01/15/2012	Common Stock	2,500	\$ 12.25	D	Â
Employee Stock Option (right to buy)	(2)	07/19/2012	Common Stock	5,000	\$ 11.31	D	Â
Employee Stock Option (right to buy)	(3)	01/18/2014	Common Stock	5,000	\$ 6	D	Â
Employee Stock Option (right to buy)	(4)	10/08/2014	Common Stock	2,500	\$ 4.41	D	Â
Employee Stock Option (right to buy)	(5)	01/17/2015	Common Stock	4,500	\$ 6.16	D	Â
Employee Stock Option (right to buy)	(6)	01/20/2016	Common Stock	3,000	\$ 16.8	D	Â
Employee Stock Option (right to buy)	(7)	07/28/2016	Common Stock	4,000	\$ 10.52	D	Â
Employee Stock Option (right to buy)	(8)	02/26/2017	Common Stock	6,500	\$ 13.5	D	Â
Employee Stock Option (right to buy)	(9)	03/03/2018	Common Stock	6,000	\$ 6.99	D	Â
Employee Stock Option (right to buy)	(10)	03/17/2019	Common Stock	6,000	\$ 4.01	D	Â
Employee Stock Option (right to buy)	(11)	03/17/2020	Common Stock	9,000	\$ 3.25	D	Â

### **Reporting Owners**

Reporting Owner Name / Address	Relationships				
. 0	Director	10% Owner	Officer	Other	
Bielasz Jennifer Kathleen C/O ARENA PHARMACEUTICALS, INC. 6166 NANCY RIDGE DRIVE SAN DIEGO, CA 92121	Â	Â	Sr. Dir. of Accounting & Cont.	Â	

## **Signatures**

Adam S. Chinnock, as	03/17/2011		
Attorney-in-Fact	03/1//201		
**Signature of Reporting Person	Date		

Reporting Owners 2

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The options vested in four equal annual installments beginning on January 15, 2003.
- (2) The options vested in four equal annual installments beginning on July 19, 2003.
- (3) The options vested in four equal annual installments beginning on June 1, 2004.
- (4) The options vested in four equal annual installments beginning on October 8, 2005.
- The options were originally for 6,000 shares of common stock, and they vested in four equal annual installments beginning on June 1, 2005. The holder exercised options to purchase 1,500 shares of common stock.
- (6) The options vested in four equal annual installments beginning on January 20, 2007.
- (7) The options vested in four equal annual installments beginning on July 28, 2007
- (8) The options vested in four equal annual installments beginning on February 26, 2008.
- The options vest in four equal annual installments, and are exercisable once vested. The first installment became exercisable on March 3, 2011, and the
- (9) 2009, the second installment became exercisable on March 3, 2010, the third installment became exercisable on March 3, 2011, and the fourth installment vests on March 3, 2012.
  - The options vest in four equal annual installments, and are exercisable once vested. The first installment became exercisable on March
- (10) 17, 2010, the second installment vests on March 17, 2011, the third installment vests on March 17, 2012, and the fourth installment vests on March 17, 2013.
- (11) The options vest in four equal annual installments beginning on March 17, 2011, and are exercisable once vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.